Drug Repurposing in Cancer Therapies
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: closed (30 December 2023) | Viewed by 529
Special Issue Editors
Interests: drug repurposing; cancer epigenetics; multidrug resistance; drug transporters; gene regulation; platinum-based anticancer drugs
Interests: cancer biomarker; evidence-based medicine; extracellular vesicles; genomics; microRNA; molecular diagnostics; non-coding RNAs; nasopharyngeal carcinoma; next-generation sequencing; non-small cell lung cancer; proteomics; drug repurposing and bioinformatics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Drug repurposing refers to the process of finding new uses for clinically approved drugs. New drug development and approval are usually timely and costly. Thus, the search for effective and durable treatment options for cancer therapy remains an unmet medical need. There has been a remarkable growth in interest in adopting the drug repurposing approach for cancer therapy in recent years. Numerous computational multi-omics tools and in silico high-throughput screening methods have been developed to facilitate the drug repurposing process. The application of drug repurposing to identify novel therapies could address the need of patients with rare cancers, which is often ignored by commercial drug development. On the other hand, the combination of repurposed drugs and conventional anticancer drugs may give rise to synergistic anticancer activity and overcome drug resistance. Some repurposed drug candidates may exhibit good efficacy but only at a dose remarkably higher than is required for their original indications. Precautions should be taken when combining repurposed drugs with anticancer agents to avoid detrimental drug-drug interactions and adverse effects.
The aim of this Special Issue is to compile a collection of updated reviews or innovative research articles about all aspects of drug repurposing for cancer therapy.
Subtopics:
(i) Circumvention of chemoresistance by drug repurposing;
(ii) Drug repurposing for treating rare cancers;
(iii) Selection of repurposed drugs for precision cancer treatment;
(iv) Biomarkers for predicting the efficacy of repurposed drugs;
(v) Strategies in identifying and validating the repurposed drugs for oncology;
(vi) Examples of successful repurposed drugs translated for cancer treatment;
(vii) Clinical challenges in drug repurposing within precision oncology and combinatorial approaches.
Dr. Kenneth K. W. To
Dr. William Cho
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug repositioning
- drug resistance
- rare cancer
- synergistic drug combination
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
